<DOC>
	<DOCNO>NCT01068470</DOCNO>
	<brief_summary>Therapy Interleukin-2 stimulate lymphocyte human become Lymphokine-activated Killer cell ( LAK ) . This study determine killer cell able kill certain standard cell-lines laboratory .</brief_summary>
	<brief_title>Determining Lymphokine Activated Killer ( LAK ) Cytotoxicity Present Patients Undergoing Interleukin-2 Therapy</brief_title>
	<detailed_description>Blood sample take patient undergoing outpatient Interleukin-2 therapy measure LAK cytotoxicity baseline , 1 cycle therapy 2 month later . The LAK cytotoxicity assay standard colorimetric assay measure lactic dehydrogenase release lysed cell .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients must undergo Interleukin2 therapy care physicians Loma Linda University Cancer Center Patients must sign give write informed consent accordance institutional federal guideline Patients undergo Interleukin2 therapy care physicians Loma Linda University Cancer Center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Interleukin-2</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Lymphokine Activated Killer cell</keyword>
</DOC>